PetCaseFinder

Peer-reviewed veterinary case report

Blood clotting changes in Cavalier King Charles Spaniels with mitral

By Tarnow, Inge et al.·Published in American journal of veterinary research·2004·The Royal Veterinary and Agricultural University·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Assessment of changes in hemostatic markers in Cavalier King Charles Spaniels with myxomatous mitral valve disease.

Species:
dog

Plain-English summary

A group of Cavalier King Charles Spaniels with heart disease known as myxomatous mitral valve disease were studied to understand their blood clotting markers. The dogs showed higher levels of a protein called fibrinogen, which is linked to heart size, and lower levels of von Willebrand factor (vWF), which helps with blood clotting, especially in those with more severe heart issues. This suggests that the heart condition may affect blood clotting in these dogs. Further research is needed to explore the risks of blood clots in dogs with this heart disease.

People also search for: Cavalier King Charles Spaniel heart disease · myxomatous mitral valve disease symptoms · dog blood clotting issues

Abstract

OBJECTIVE: To evaluate markers of hemostasis and their relationship to the degree of mitral regurgitation (MR) and platelet function in Cavalier King Charles Spaniels (CKCSs) with myxomatous mitral valve disease. ANIMALS: 76 clinically healthy CKCSs and 24 control dogs. PROCEDURE: All dogs underwent echocardiographic examination; various hemostatic, hematologic, and biochemical variables were evaluated in blood. The CKCSs were allocated to 1 of 3 groups on the basis of MR severity. In 8 control dogs and 8 CKCSs, plasma von Willebrand factor (vWF) multimer analysis was performed. RESULTS: Compared with control dogs, plasma fibrinogen concentration was higher in all CKCSs and related to left ventricular end diastolic diameter and left atrial-to-aortic root ratio among all CKCSs. The activated partial thromboplastin times and plasma D-dimer concentration were similar among the 4 groups. Plasma vWF concentration was lower in CKCSs with moderate to severe MR, compared with that of CKCSs with no MR and control dogs. There was a relationship between plasma vWF concentration and platelet function in CKCSs but not in control dogs. In 4 CKCSs with moderate to severe MR and low plasma vWF concentration, amounts of vWF high-molecular-weight multimers (HMWMs) were low. CONCLUSIONS AND CLINICAL RELEVANCE: In CKCSs, MR appeared to be associated with a low plasma vWF concentration and likely a loss of vWF HMWMs (possibly through their destruction via shear stress to the blood). The importance of the changes in plasma fibrinogen concentration and the thromboembolic risk in dogs with MR remain to be investigated.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15631028/